Floatz logo

bp1001

Ph1 Positive CML

Bio-Path Holdings, Inc.nucleic_acidPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Ph1 Positive CML cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

bp1001 is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →
myelodysplastic syndromeDormant
CCC
Indicative ·
51 / 100
View asset →
chronic myeloid leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →